Q-omics provides the consensus-scored MT3 profile across patient tissues and cancer cell-line models. MT3 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, MT3 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, MT3 RNA expression shows 12,196 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight SKCM, KIRP, and TGCT as cancer lineages where MT3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MT3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MT3 survival associations across molecular data types. MT3 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MT3 RNA expression–survival associations across cancer types. High MT3 expression shows unfavorable associations in LGG and ESCA, but favorable associations in SKCM, STAD, BLCA and BRCA. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SKCM as the clearest survival context for MT3 RNA expression.
This table summarizes MT3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MT3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MT3 shows lower tumor expression in KIRP, HNSC and STAD and higher tumor expression in LIHC, UCEC and KIRC. The KIRP box plot shows higher MT3 RNA expression in normal versus tumor tissue (log2 FC = −1.647, t-test p < 0.001).
This table shows molecular features associated with MT3 in patient tissues and cancer cell lines. In patient samples, MT3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, MT3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_SCLC, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and CNS.
